Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool June 21, 2011 Frank Vinluan	GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV.
Chemistry World September 25, 2013 Phillip Broadwith	New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out.
The Motley Fool June 25, 2010 Brian Orelli	Merck Breathes Life Into an Acquired Pipeline The acquisition is paying off with newly approved drugs.
The Motley Fool September 20, 2007 Brian Lawler	Discovering Pharmacopeia Pharma investors should watch Pharmacopeia, a tiny drug company with several interesting compounds in development.
The Motley Fool May 21, 2007 Brian Lawler	DUSA's Orphan Isn't Unique The pharmaceutical gets "orphan drug" status for its lead compound. Investors, take note.
The Motley Fool February 10, 2011 Brian Orelli	Breathe Easier, Join the Competition Novartis' strategy is a good one.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool April 15, 2011 Frank Vinluan	GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands."
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
The Motley Fool July 10, 2007 Brian Lawler	Adolor Tries Again Adolor continues work on its second drug candidate. Investors will have to wait until early 2008 for some data to sink their teeth into.
The Motley Fool May 14, 2007 Brian Lawler	Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note.
The Motley Fool October 25, 2007 Brian Lawler	Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool June 5, 2007 Brian Lawler	Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
Chemistry World September 10, 2014 Emma Stoye	Cipla targets asthma market with Advair copy Indian pharma company Cipla has begun selling a generic version of GlaxoSmithKline's combination asthma treatment Advair (fluticasone/salmeterol) in Germany and Sweden.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
The Motley Fool September 7, 2007 Brian Orelli	Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug.
The Motley Fool August 4, 2011 Frank Vinluan	Skin in the Game: How Acne Skin Care Fits GSK's Drug Portfolio Strategy GSK thinks long-term with this acne skin care product.
BusinessWeek October 4, 2004 Kerry Capell	Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool November 27, 2006 Brian Lawler	Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool April 26, 2007 Mike Havrilla	Xenoport Soothes Investors' Restless Hearts Shares surge on positive trial results of an experimental drug for restless legs. Investors, take note.
The Motley Fool September 30, 2005 Stephen D. Simpson	Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note.
The Motley Fool May 22, 2009 Brian Orelli	Novartis Breathes Easier Novartis' investors can breathe a little easier. The company's new treatment for chronic obstructive pulmonary disease -- a.k.a. "smoker's lung" -- passed its three phase 3 trials without so much as a cough.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.
Bio-IT World May 2006 Kevin Davies	Personalized Medicine's Rosy Picture GlaxoSmithKline's head of genetics research, Allen Roses, says that pharmacogenetics is having a profound impact on the stratifying of patients, the minimization of adverse events, and the expedited passage of drug candidates through clinical trials.
The Motley Fool September 11, 2009 Brian Orelli	A Congress Full of Headaches And no drug to fix it. Merck's migraine drugs that block the calcitonin gene-related peptide receptor had such potential to treat what ails me and our government servants. That is, until side effects started popping up.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
Chemistry World January 30, 2007 Bea Perks	BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
The Motley Fool August 24, 2007 Brian Lawler	Flamel Under Fire Stocks fall when study fails to show drug's superiority. Investors, take note.
The Motley Fool June 29, 2009 Brian Orelli	Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug.
Pharmaceutical Executive April 1, 2011	Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition.
The Motley Fool June 14, 2011 Frank Vinluan	GSK Epilepsy Drug Approved by FDA GlaxoSmithKline and drug partner Valeant Pharmaceuticals have received U.S. Food and Drug Administration approval on a new epilepsy drug, but it must be classified as a controlled substance.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool November 28, 2008 Brian Orelli	Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug?
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
The Motley Fool September 9, 2008 Brian Orelli	Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.